Glioma of Brain
28
5
8
5
Key Insights
Highlights
Success Rate
56% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
4 terminated out of 28 trials
55.6%
-30.9% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (28)
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
A Study Utilizing Escitalopram in Glioma Patients
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
Blood Biomarker Signature in Glioma
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients
Glioma Microenvironment an Exploratory Study
Azoles Targeting Recurrent High Grade Gliomas
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients